Jubilant HollisterStier Announces New President and Upcoming Availability of Expanded Production Capacity for Sterile Injectables
Jubilant HollisterStier (JHS), a U.S.-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, has appointed Chris Preti as President. He brings more than 25 years of pharmaceutical industry experience in R&D, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President.
Jubilant HollisterStier, a Canada-based pharmaceutical contract manufacturing organization (CMO), in a deal with the Government of Quebec, announced a $77 million capacity expansion at its manufacturing facility in Montreal.
NOIDA, India, May 30, 2022 /PRNewswire/ -- Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of the Biomedical Advanced Research and Development Authority (BARDA), within the US Department of Health and Human Services. The effort was funded under the American Rescue Plan, this agreement will enable the Company to double its injectable filling production capacity at a total cost of $193 million, at its Spokane, Washington manufacturing facility. This will be completed by 2025.
Jubilant HollisterStier to manufacture COVAXIN for the U.S. and Canadian markets.
Jubilant HollisterStier to manufacture COVAXIN for the U.S. and Canadian markets.
The dire need for manufacturing capacity and a pledge of a rapid ramp up of vaccines and treatments to battle Covid-19 have left companies scrambling to expand internally, and CDMOs are bringing home serious revenue as a result. That’s meant a bowl of cash to work with, and now a Washington CDMO is splashing out a new expansion.
Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373. Under the terms of the agreement, Jubilant HollisterStier’s Spokane, WA facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the U.S.
Jubilant Life Sciences Ltd., an integrated global pharmaceuticals and life sciences company, recently announced that its wholly-owned subsidiary, Jubilant Pharma Limited, through its contract manufacturing organization (CMO) subsidiary, Jubilant HollisterStier LLC, has signed a new contract with Eli Lilly for manufacturing of a treatment for COVID-19.
Jubilant HollisterStier Contract Manufacturing & Services is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and sterile and non-sterile topicals and liquids. Our facilities in North America provide specialized manufacturing services for the pharmaceutical and biopharmaceutical industries. We provide a full-range of support and services to streamline the manufacturing process such as on-site assistance from process qualifications through product release. Experienced Project Managers work with our clients and our expert staff throughout the manufacturing process to ensure that projects are processed efficiently and safely. A Jubilant Pharma Company.